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oligoprogression or dominant tumour/local control. LC is highest 
for lung tumours which received the highest SBRT doses. 
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Purpose: Primary hepatocellular (HCC) and secondary liver 
metastases (METS) is a growing problem. Despite the increasing 
use of liver stereotactic body radiotherapy (SBRT), there is a lack 
of a predictive model to understand which patients benefit from 
treatment. This study developed a model to improve patient 
selection for radical radiotherapy for liver malignancies.  
Methods and Materials: Two hundred and twelve (HCC (31%), 
METS (69%)) patients were identified. We excluded those 
receiving low dose palliative radiation. Patients dying within four 
months were deemed to have failed to benefit from radiation. 
Both patient and tumour parameters were selected for 
univariate analysis. Patient factors included age, sex and liver 
function (Child-Pugh (CP) score, serum albumin (ALB), total 
bilirubin, prothrombin time, presence of ascites). Tumour 
factors included gross tumour volume (GTV), number of lesions, 
presence of extrahepatic disease (ED), previous treatments 
(resection, chemotherapy, chemoembolization) and primary 
disease site if metastatic. Multivariable regression analysis was 
used to develop a clinical predictive tool.  
Results: For HCC, CP score and a larger GTV were found to be 
significant predictors of early death. For the METS group, ALB, 
presence of ED and colorectal primary were significant 
predictors. For the combined set, CP score (HR = 0.7), ALB (HR = 
1.1), previous resection (HR = 5.2) and presence of ED (HR = 0.4) 
were significant predictors. Chi-squared analysis showed a 
significant (p < 0.01) reduction in deviance indicating that the 
model has good predictive value. ANOVA indicated that while 
each variable significantly reduced the residual deviance, the 
model is not saturated.  
Conclusions: A model was developed to identify patients who 
are unlikely to benefit from radiation. The model is not saturated 
and additional variables need to be identified. Multi-institutional 
collaboration is required to obtain a larger sample size, as single 
centres are unlikely to obtain sufficient numbers for this disease 
site. Until then, all patients meeting commonly accepted liver 
SBRT eligibility should be offered radiation. 
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Purpose: Head and neck basal cell carcinoma (HN-BCC) is mainly 
managed by primary surgery. Radiotherapy (RT) is sometimes 
used for aggressive form BCC with adverse pathological features 
or occasionally as a definitive treatment alternative to surgery 
to enhance locoregional control (LRC). This study reviews 
outcome of HN-BCC following mega-voltage RT in our institution. 
Methods and Materials: All HN-BCC received definitive or post- 
operative RT (PORT) between 1998 and 2014 were reviewed. 
Physician reported cosmetic outcome were recorded as a binary 
valuable (“good” or “poor”). Locoregional control (LRC), 
recurrence-free survival (RFS), and overall survival (OS) were 
calculated for all cases and for cases receiving definitive RT. 
Univariate analysis (UVA) assessed the association of tumour 
factors and LRC. 
Results: A total of 111 consecutive HN-BCC were identified 
including 71 newly diagnosed and 40 recurrent BCC (rBCC). 
Median age was 76 years. All cases were aggressive form BCC 
with initial diameter > 1 cm (n = 109) patients, > 2 recurrence (n 
= 24) or extra-cutaneous extension (n = 30). Definitive RT (45-70 
Gy at 1.8-4.5 Gy per fraction) was given in 73 (65.7%) cases for 
the following reasons: technically not suited for surgery (n = 20), 
cosmetic consideration (n = 42), and high operation risk due to 
age or comorbidities (n = 11). PORT (50-66 Gy at 1.8-2 Gy per 
fraction) was given in 38 cases for either adverse pathological 
features (compromised margins, deep invasion, and positive 
lymph nodes) (n = 26/38) or history of multiple recurrences (n = 
14/38). Chemotherapy was only used in six (5.4%) patients in 
adjuvant setting. Median follow up was 4.7 years. Five-year LRC, 
RFS, and OS were 87%, 82%, and 93% for the entire cohort and 
85%, 82%, and 96% for definitive RT subset. UVA revealed that 
rBCC [hazard ratio (HR) 8.03 (95% CI: 1.04-61.9), p = 0.04], 
primary arising from peri-orbital/peri-auricular region [HR 0.03 
(1.06-9.13), p = 0.05], tumour size [HR 1.32 (1.08-1.61), p < 
0.01], lymph node involvement (N+) [HR 3.7 (1.11-12.3), p = 
0.03] and Stage III/IV [HR 3.16 (1.19-8.36), p = 0.03] were 
associated with increased risk of locoregional recurrence. 
Tumour size [HR 1.23 (1.02-1.47), p = 0.02] and N+ [HR 4.84 
(1.57-14.95), p < 0.01] had a significant poor OS. Physician 
reported cosmetic outcome were good in 70/82 (85%) patients. 
Conclusions: This study shows that RT is a valid alternative 
option for HN-BCC with a high LRC when used as single modality 
or in PORT setting with good overall cosmetic outcome. 
Recurrent tumour, size, nodal involvement and stage are 
associated with increased risk of recurrence. 
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Purpose: The Phoenix definition of biochemical failure (BF) 
(nadir+2) may overestimate cure rates after low dose rate 
prostate brachytherapy (LDR-PB). The purpose of this study is to 
assess long-term PSA stability after LDR-PB and predictive factors 
of eventual BF for those with a slowly rising PSA. 
Methods and Materials: 2772 low or intermediate-risk prostate 
cancers underwent Iodine-125 LDR-PB monotherapy between 
1998 and 2010. 49.7% received androgen deprivation (ADT) prior 
to LDR-PB (treatment policy: six months). Patients with less than 
36 months follow up were excluded (n = 433). Clinical 
characteristics, dosimetric parameters and sequential PSA 
readings were retrieved from a prospective provincial database. 
A rising PSA was considered to be PSA ≥ 0.2 ng/mL with an 
increase ≥ 0.1 ng/mL over previous two years. The Phoenix 
definition was used to identify BF. Patients were classified as: 1) 
stable PSA (cured); 2) rising PSA (without BF); or 3) BF. The three 
groups were compared according to clinical, dosimetric and post-
treatment parameters. Multivariate analysis was performed on 
the cured and failed groups to determine variables predicting for 
failure. Logistic regression model was applied with cross 
validation to test for model accuracy. ROC curves were obtained 
for patients with and without ADT to determine predictive cut-
offs for BF. 
Results: Median follow up is 89 months (37-199); median age at 
implant 66 years (43-84). Majority of patients (80.7%) had clinical 
Stage T1-T2a, 55% had Gleason score ≤ 6 and median baseline 
PSA was 6.5 ng/mL(0.3-40 ng/mL). 59% were intermediate-risk. 
Among the 2339 patients analyzed, 2004 (85.7%) had a stable PSA 
and were considered cured [median PSA at 60 months (PSA-60): 
0.04ng/mL], 145 (6.2%) had a rising PSA (PSA-60: 0.27 ng/mL) 
and 190 (8.1%) had BF. PSA nadirs for the three groups were 
respectively 0.03 (cured), 0.16 (rising PSA) and 0.51 ng/mL (BF) 
(p < 0.0001). For patients with no prior ADT, the variables 
associated with failure are PSA nadir (OR: 20.6 p < 0.0001) and 
PSA-60 (OR: 18.3 p < 0.0001). If the model is applied to the rising 
PSA group, using a PSA-60 cut-off of 0.3 ng/mL (sensitivity: 85%, 
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specificity: 98.1%), the risk of failure is 9.8% (8/82) for patients 
not having received ADT. For patients who received ADT, the 
predictive factors of failure are PSA-60 (OR:53.9 p < 0.0001) and 
T-Stage (OR:0.25 p = 0.0008). Using this model and a PSA-60 cut-
off of 0.1 ng/mL (sensitivity: 85%, specificity: 92.9%), the 
predicted risk of BF in the rising PSA group is 53.7% (36/56). 
Taking into account the two predictive models, the anticipated 
cure rate for the entire cohort is 89.7%. 
Conclusions: Patients treated with LDR-PB monotherapy and 
whose PSA-60 is ≤ 0.3 ng/mL are highly likely to be cured even if 
they experienced a slight PSA rise. However, for patients who 
also received ADT, a stricter cut-off of 0.1 ng/mL may be 
appropriate. 
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Purpose:  The purpose of this study was to explore the cancer 
demographics in First Nations (FN) versus general population 
living in the remote island communities of Haida Gwaii, with 
similar access to cancer care services. 
Methods and Materials:  Medical charts of all 587 patients 
diagnosed with cancer from a period of 1970 until 2014 were 
retrieved from the British Columbia Cancer Agency registry and 
Northern Health database. Patients were categorized as FN or 
general population based on knowledge from community leader 
co-investigators. Estimates on breast cancer incidence in the 
period of 2001-2010 were calculated from the number of women 
in each community as per the Canadian Cancer Society census 
for that decade. Chi-square associations and multivariable Cox 
model was used to evaluate the association between FN versus 
non-FN status and mortality, after adjusting for clinical and 
treatment variables. 
Results:  A total of 587 patient charts were analyzed, with a 
median age at diagnosis of 62 years. Overall, 26% of cancer 
diagnoses were in patients of FN descent. Overall, 18% had 
confirmed smoking status, and 34% had a baseline performance 
status of 0-1. The most common cancer primary was genito-
urinary (GU: 17%), followed by gastro-intestinal (GI: 14%), breast 
(13%) and lung cancers (13%), while 14% were unknown. Stage I-
II presentation was seen in 21% and Stage III-IV was seen in 12% 
of the entire cohort. Surgery was performed in 26%, radiation 
therapy in 16% and chemotherapy was prescribed to 18%, but the 
status on cancer treatment was unknown in 54% of the cohort. 
The median number of trips made from the patient's hometown, 
up to and including initial treatment date was two (range, 1-5), 
with no difference between FN and non-FN group. Comparing FN 
versus non-FN population, significant clinical and treatment 
characteristics were: males (47% versus 58%; p = 0.03), breast 
cancer (23% versus 11%; p < 0.001), and GI cancers (22% versus 
13%; p < 0.001). There was no significant difference in overall 
survival (hazard ratio=1.28, 95% confidence interval: 0.77-2.16; 
p = 0.34).The estimated annual incidence for breast cancer in FN 
group was 2.2 cases per 1000, and 1.47 cases per 1000 for the 
non-FN population, while the Canadian estimate is 0.97 per 1000. 
Conclusions:  Breast cancer was more commonly seen in FN with 
an estimated 50% increased incidence of breast cancer as 
compared to the general population in Haida Gwaii, though the 
study sample size is small. The cancer care pathway and overall 
survival appear similar between the FN and non-FN cancer 
patients. 
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Purpose:  In the past decade, health care services for patients 
diagnosed with brain metastases have changed considerably with 
respect to decision-making, diagnostic sensitivity, systemic 
therapy options, surgical/radiosurgical approaches, and 
interdisciplinary management, including early palliative care 
support. Considering the combined effects of these changes, we 
hypothesized that, when compared to our institutional historical 
series of 2000-2005 (published 2011), survival has improved for 
those brain metastases patients seen between 2011-2015.  
Methods and Materials: From January 2011 to December 2015, 
patients with a new diagnosis of brain metastases referred to our 
regional cancer centre were triaged by a clinical nurse specialist, 
including after-hours referrals to the on-call radiation 
oncologists. Prophylactic cranial irradiation, hematological 
malignancies, non-Canadian, and cases without a consultation 
visit were excluded. Historical data from 2000-2005 was cleaned 
and updated; out-of-province cases lost to follow up were 
excluded. Survival time was measured from date of CT/MR 
diagnosis to date of death or censored at last contact. 
Proportional hazard regression model was pre-specified to test 
period effect (2011-15 versus 2000-05), adjusting for age and 
primary (lung, breast, melanoma, others). Prior to survival 
analysis, a clinically meaningful median survival gain was defined 
as one month or more for lung, breast and melanoma primaries. 
Results: From 2011-15, 688 cases were referred, of whom 675 
were included in this analysis (82% have died); from 2000-05, 555 
cases. Median age was 63 years and 61 years, respectively. The 
2011-15 cohort comprised of lung, breast, melanoma, and other 
cancers in 54%, 17%, 7.8% and 21% respectively; for 2000-05, 62%, 
13%, 4.5% and 21%. Median survival was 3.9 months for the 2011-
15 cohort (CL 3.4-4.2 months; 36% at 6 months) and 3.1 months 
for 2000-05 (CL 2.8-3.5 months; 30% at six months), Log rank p = 
0.0002 (lung 3.8 months versus 3.0 months; breast 3.8 months 
versus 4.0 months; melanoma 5.9 months versus 4.7 months). 
Adjusted for age, survival improvement was significant for lung 
(HR 0.78, CL 0.67-0.91), but not breast (HR 0.83, CL 0.61-1.1) 
nor melanoma (HR 0.76, CL 0.43-1.3). 
Conclusions: Even though the pre-defined magnitude of survival 
gain was not observed, the combined effects of advances in 
diagnosis, therapeutic strategies, and interdisciplinary 
collaboration on patients with brain metastases were associated 
with a modest improvement in survival outcome. While 
subgroups of patients might have benefited more from aggressive 
management, two out of three patients succumbed within six 
months of diagnosis. Palliative, supportive and transitional care 
services remain a clinical priority for the majority of brain 
metastases patients. 
 
97 CARO FELLOWSHIP 
IMAGE GUIDED BRACHYTHERAPY IN CERVICAL CANCER: A 
COMPARISON BETWEEN INTRACAVITARY AND COMBINED 
INTRACAVITARY/INTERSTITIAL BRACHYTHERAPY IN REGARD TO 
DOSES TO HR CTV, OARS AND LATE MORBIDITY – EARLY RESULTS 
FROM THE EMBRACE STUDY IN 999 PATIENTS  
Israël Fortin1, Kari Tanderup2, Christine Haie-Meder3, Jacob 
Christian Lindergaard2, Umesh Mahantshetty4, Barbara 
Seguedin5, Ina M. Jürgenliemk-Schulz6, Peter Hoskin7, Christian 
Kirisits8, Richard Pötter8 
1Centre hospitalier de l, Montreal, QC 
2Aarhus University, Aarhus, Denmark 
3Institut Gustave Roussy, Paris, France 
4Tata Memorial Hospital, Mumbai, India 
5Institute of Oncology, Ljubljana, Slovenia 
6University Medical Center Utrecht, Utrecht, The Netherlands 
